269 related articles for article (PubMed ID: 38674231)
1. Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma.
Pezzicoli G; Ciciriello F; Musci V; Minei S; Biasi A; Ragno A; Cafforio P; Rizzo M
Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674231
[TBL] [Abstract][Full Text] [Related]
2. Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need.
Montazeri K; Sonpavde G
Expert Rev Anticancer Ther; 2021 Mar; 21(3):299-313. PubMed ID: 33249937
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy.
Tully KH; Jütte H; Wirtz RM; Jarczyk J; Santiago-Walker A; Zengerling F; Breyer J; Sikic D; Kriegmair MC; von Hardenberg J; Wullich B; Taubert H; Weyerer V; Stoehr R; Bolenz C; Burger M; Porubsky S; Hartmann A; Roghmann F; Erben P; Eckstein M
Urology; 2021 Nov; 157():93-101. PubMed ID: 34153367
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma.
Fleming S; Gifkins D; Resnick HE; Shalaby W; Rosenberg P; Gaj C; Maio V; Crawford A; Lu-Yao G; Gao J; Siefker-Radtke A
Clin Genitourin Cancer; 2024 Jun; 22(3):102054. PubMed ID: 38457853
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.
Necchi A; Lo Vullo S; Raggi D; Gloghini A; Giannatempo P; Colecchia M; Mariani L
Eur Urol Focus; 2019 Sep; 5(5):853-856. PubMed ID: 29525380
[TBL] [Abstract][Full Text] [Related]
6. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
Agarwal N; Pal SK; Hahn AW; Nussenzveig RH; Pond GR; Gupta SV; Wang J; Bilen MA; Naik G; Ghatalia P; Hoimes CJ; Gopalakrishnan D; Barata PC; Drakaki A; Faltas BM; Kiedrowski LA; Lanman RB; Nagy RJ; Vogelzang NJ; Boucher KM; Vaishampayan UN; Sonpavde G; Grivas P
Cancer; 2018 May; 124(10):2115-2124. PubMed ID: 29517810
[TBL] [Abstract][Full Text] [Related]
7. Current Therapy for Metastatic Urothelial Carcinoma.
Nadal R; Clara JA; Valderrama BP; Bellmunt J
Hematol Oncol Clin North Am; 2021 Jun; 35(3):469-493. PubMed ID: 33958146
[TBL] [Abstract][Full Text] [Related]
8. The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
Lavoie JM; Sridhar SS; Ong M; North S; Alimohamed N; McLeod D; Eigl BJ
Oncologist; 2021 Aug; 26(8):e1381-e1394. PubMed ID: 34028134
[TBL] [Abstract][Full Text] [Related]
9. Urothelial Bladder Cancer: Genomic Alterations in Fibroblast Growth Factor Receptor.
Bou Zerdan M; Bratslavsky G; Jacob J; Ross J; Huang R; Basnet A
Mol Diagn Ther; 2023 Jul; 27(4):475-485. PubMed ID: 37195586
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor receptors across urothelial carcinoma landscape.
Ertl IE; Shariat SF; Mostafaei H; Ilijazi D; Loriot Y
Curr Opin Urol; 2020 Jul; 30(4):557-565. PubMed ID: 32452999
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis.
Hepp Z; Shah SN; Smoyer K; Vadagam P
J Manag Care Spec Pharm; 2021 Feb; 27(2):240-255. PubMed ID: 33355035
[No Abstract] [Full Text] [Related]
12. [Innovations in systemic treatment of urothelial carcinoma].
Thibault C; Gross-Goupil M
Bull Cancer; 2020 Jun; 107(5S):S6-S16. PubMed ID: 32620209
[TBL] [Abstract][Full Text] [Related]
13. The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort.
Nielsen TJ; Varga MG; Cronister CT; Ring BZ; Seitz RS; Ross DT; Schweitzer BL; McGregor K
Cancer Immunol Immunother; 2023 Jul; 72(7):2075-2086. PubMed ID: 36806983
[TBL] [Abstract][Full Text] [Related]
14. Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.
Necchi A; Ramlau R; Falcón González A; Chaudhry A; Todenhöfer T; Tahbaz R; Fontana E; Giannatempo P; Deville JL; Pouessel D; Yoon S; Powles T; Bernat M; Häckl M; Marszewska M; McKernan P; Saulay M; Scaleia F; Engelhardt M; Loriot Y; Siefker-Radtke A; De Santis M
JNCI Cancer Spectr; 2024 Apr; 8(3):. PubMed ID: 38627238
[TBL] [Abstract][Full Text] [Related]
15. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
[TBL] [Abstract][Full Text] [Related]
16. Emerging agents for the treatment of metastatic urothelial cancer.
Kwon WA; Seo HK
Investig Clin Urol; 2021 May; 62(3):243-255. PubMed ID: 33943047
[TBL] [Abstract][Full Text] [Related]
17. Targeting FGFR in bladder cancer: ready for clinical practice?
De Keukeleire S; De Maeseneer D; Jacobs C; Rottey S
Acta Clin Belg; 2020 Feb; 75(1):49-56. PubMed ID: 31671027
[No Abstract] [Full Text] [Related]
18. Frequency of next-generation sequencing, prevalence of targetable mutations and response to targeted therapies amongst patients with metastatic urothelial cancer in Ireland: a multi-centre retrospective study of real-world data.
Ronan K; Jordan E; Leonard C; McDermott R
Ir J Med Sci; 2024 Jun; 193(3):1155-1161. PubMed ID: 37947995
[TBL] [Abstract][Full Text] [Related]
19. Emerging treatments in advanced urothelial cancer.
Alhalabi O; Campbell M; Shah A; Siefker-Radtke A; Gao J
Curr Opin Oncol; 2020 May; 32(3):232-239. PubMed ID: 32209822
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer.
Garje R; An J; Obeidat M; Kumar K; Yasin HA; Zakharia Y
Oncologist; 2020 Nov; 25(11):e1711-e1719. PubMed ID: 32790011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
